Physician profile
Laith Ali
NPI 1659866515
$3,258.24
in general payments reported to CMS, 2019-2025
16 companies · $741 in 2025
The $741 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $101 · 2024: $2,416 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932 · Grant: $1,063 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.14 |
| Grant | $1,063.30 |
| Education | $161.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,657.44 | 2024-2025 | Stingray, Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor |
| Abiomed | $348.45 | 2024-2025 | Impella |
| Medtronic, INC. | $286.61 | 2024-2025 | Onyx Frontier, Symplicity G3 |
| Shockwave Medical, INC | $177.24 | 2025 | |
| Edwards Lifesciences Corporation | $173.68 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Penumbra, INC. | $169.57 | 2024-2025 | Indigo System |
| Inari Medical, INC. | $166.37 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $101.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.92 | 2025 | |
| Abbott Laboratories | $24.93 | 2024 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.82 | 2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $16.32 | 2025 | Wainua |
| Recor Medical INC | $15.96 | 2025 | Paradise Ultrasound Renal Denervation System |
| Regeneron Healthcare Solutions, INC. | $15.18 | 2025 | Evkeeza |
| Acist Medical Systems, INC. | $14.30 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $14.14 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laith Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.